Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia
the ONA take:
Recent meta-analyses showed that incidence of fever and mortality rate were reduced in patients with neutropenia after chemotherapy when antibiotic prophylaxis was administered.
As fluoroquinolones appear to be most effective and well tolerated, a German team changed the antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).
In this retrospective study, they compare the efficacy and development of bacterial resistance with the two prophylaxis regimens over a period of more than 4 years via a standard questionnaire.
The findings show no significant difference in incidence of fever between the COT/COL group and the CIP group.
In addition, the rates of both microbiologically and clinically documented infections were similar, as well as rates of gram-positive and gram-negative bacteria.
No increases in resistance rates or cases with Clostridium difficile-associated diarrhea in the CIP group were noted.
The researchers conclude antibiotic prophylaxis with CIP and COT/COL in patients with AML was similarly effective with no increase in bacterial resistance.
Antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with AML.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|